fludarabine phosphate has been researched along with Diabetes Mellitus, Type 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Z; Hering, B; Heuss, N; Kirchhof, N; Levay-Young, B; Sozen, H; Sutherland, DE; Wu, T | 1 |
| Blazar, BR; Guo, Z; Hering, BJ; Heuss, N; Kalscheuer, H; Pan, Y; Sozen, H; Sutherland, DE; Wu, T | 1 |
2 other study(ies) available for fludarabine phosphate and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy.
Topics: Animals; Bone Marrow Transplantation; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Graft Survival; Immune Tolerance; Immunosuppressive Agents; Islets of Langerhans Transplantation; Major Histocompatibility Complex; Male; Mice; Mice, Inbred NOD; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine Phosphate | 2002 |
A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice.
Topics: Animals; Bone Marrow; Cyclophosphamide; Diabetes Mellitus, Type 1; Female; Immunosuppressive Agents; Islets of Langerhans Transplantation; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Vidarabine Phosphate | 2003 |